A major advance in cancer research is occurring with the use of mini-antibodies to reactivate mutated p53. This essential malignant inhibitor protein is frequently disabled in many forms of cancer, leading uncontrolled https://express-page.com/story7443595/mini-antibodies-reactivate-tumor-suppressor-p53-the-new-pathway-for-tumor-management